CanaQuest Medical Corp.

CANQF

CA1372201097

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:49:19 2024-07-10 pm EDT			5-day change	1st Jan Change
0.0777 ^USD	-13.57%		-7.39%	-67.62%

Jun. 11	CanaQuest Medical Corp. Announces Appointment of Dr. Paul Dick, Chairman of Advisory Board	CI
2023	NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	CI

CanaQuest Medical Corp. Announces Appointment of Dr. Paul Dick, Chairman of Advisory Board

June 11, 2024 at 09:00 am EDT

CanaQuest Medical Corp. announced strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. Chairman of Advisory Board - Dr. Paul Dick, DVM, MSc, Paul Dick & Associates, over 30 years of experience in the pharmaceutical and animal health industries, served on several boards: Animal Health Institute, President of the Ontario Veterinary Medical Association.

Latest news about CanaQuest Medical Corp.

CanaQuest Medical Corp. Announces Appointment of Dr. Paul Dick, Chairman of Advisory Board	Jun. 11	CI
NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	23-10-31	CI
CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	23-10-25	CI
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent	23-09-19	CI
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD	22-12-08	CI
CanaQuest Medical Corp. announced a financing transaction	22-10-25	CI
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US	22-09-08	CI
CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications	21-04-07	CI
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre	21-03-11	CI
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc	21-02-02	CI
CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine®	20-07-14	CI
CanaQuest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	20-02-06	CI
CanaQuest Medical Corp. will Change its Ticker to CANQ.F from ADYNF	19-04-08	CI
Algae Dynamics Corp Ordinary Shares will Change its Name to CanaQuest Medical Corporation Ordinary Shares	19-04-08	CI
Algae Dynamics Corp. announced that it has received CAD 0.1 million in funding	18-10-18	CI
Algae Dynamics Corp. announced that it has received CAD 0.52 million in funding	18-08-02	CI
Algae Dynamics Corp. Secures Bulk Cannabis Supply Agreement for Collaboration Partners	18-08-02	CI
Algae Dynamics Corp. announced that it has received $0.5 million in funding from Teewinot Life Sciences Corp.	17-11-14	CI
Algae Dynamics Corp. announced that it expects to receive $0.5 million in funding from Teewinot Life Sciences Corp.	17-10-26	CI
Algae Dynamics Corp. Enters into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products	17-08-16	CI
Algae Dynamics Corp Announces Joint Venture with ARA- Avanti Rx Analytics Inc. to Formulate, Manufacture and Sell Products Utilizing Algae, Hemp Cannabis Oils	17-04-19	CI
Algae Dynamics Seeks Partner	17-03-16	CI
Algae Dynamics Corp Announces Research Agreement with University of Western Ontario to Investigate the Use of Cannabis Derivatives	17-03-13	CI
Algae Dynamics Corp. Announces Research Agreement with University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer	17-02-25	CI
Algae Dynamics Corp. Auditor Raises 'Going Concern' Doubt	16-07-04	CI

Chart CanaQuest Medical Corp.

Duration

Period

More charts

Company Profile

CanaQuest Medical Corporation is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is also focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder (PTSD), including addiction. It provides a novel master formulation derived from cannabidiol (CBD) + IP formula. The Company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the master formulation, branded as Mentanine, is available for sale via the Companyâs store in the United States. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects. The Companyâs wholly owned subsidiary is ADC BioMedical Corp.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
CANAQUEST MEDICAL CORP.	-67.62%	1.66M
DONG-E-E-JIAO CO.,LTD.	+17.11%	5.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-35.20%	3.43B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-2.64%	3.05B
TASLY PHARMACEUTICAL GROUP CO., LTD	-25.79%	2.59B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-14.23%	2.2B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+40.50%	1.86B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+32.83%	1.36B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-16.36%	1.37B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+41.90%	1.38B

Alternative Medicine